Clinical Trials Browser

silmitasertib × 90 days × Clear all

NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase 1/2 Recruiting

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma